Alnylam Pharmaceuticals Stock Price on December 22, 2024
| ALNY Stock | USD 245.44 6.57 2.75% |
Below is the normalized historical share price chart for Alnylam Pharmaceuticals extending back to May 28, 2004. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Alnylam Pharmaceuticals stands at 245.44, as last reported on the 22nd of December, with the highest price reaching 247.16 and the lowest price hitting 236.45 during the day.
If you're considering investing in Alnylam Stock, it is important to understand the factors that can impact its price. Alnylam Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0614, which signifies that the company had a -0.0614% return per unit of risk over the last 3 months. Alnylam Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Alnylam Pharmaceuticals' Mean Deviation of 1.45, risk adjusted performance of (0.05), and Standard Deviation of 2.16 to double-check the risk estimate we provide.
At this time, Alnylam Pharmaceuticals' Liabilities And Stockholders Equity is fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 7.2 B in 2024, despite the fact that Total Stockholder Equity is likely to grow to (209.6 M). . At this time, Alnylam Pharmaceuticals' Price Earnings To Growth Ratio is fairly stable compared to the past year. Price To Operating Cash Flows Ratio is likely to rise to 241.02 in 2024, whereas Price To Sales Ratio is likely to drop 12.42 in 2024. Alnylam Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 28th of May 2004 | 200 Day MA 221.1985 | 50 Day MA 264.4344 | Beta 0.386 |
Alnylam |
Sharpe Ratio = -0.0614
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALNY |
Estimated Market Risk
| 2.17 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Alnylam Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alnylam Pharmaceuticals by adding Alnylam Pharmaceuticals to a well-diversified portfolio.
Price Book 978.6986 | Enterprise Value Ebitda 204.8549 | Price Sales 15.1123 | Shares Float 128.4 M | Wall Street Target Price 299.1067 |
Related Headline
Halozyme Therapeutics Headline on 22nd of December 2024
Disposition of 10000 shares by Nicole LaBrosse of Halozyme T... by Nicole LaBrosse
Filed transaction by Halozyme Therapeutics Officer Svp, Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Alnylam Pharmaceuticals Valuation on December 22, 2024
It is possible to determine the worth of Alnylam Pharmaceuticals on a given historical date. On December 22, 2024 Alnylam was worth 239.45 at the beginning of the trading date compared to the closed value of 245.44. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Alnylam Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Alnylam Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Alnylam Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Alnylam Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 239.45 | 247.16 | 236.45 | 245.44 | 1,088,500 | |
12/22/2024 | 239.45 | 247.16 | 236.45 | 245.44 | 0.00 |
| Backtest Alnylam Pharmaceuticals | | | Alnylam Pharmaceuticals History | | | Alnylam Pharmaceuticals Valuation | Previous |
Alnylam Pharmaceuticals Trading Date Momentum on December 22, 2024
| On December 22 2024 Alnylam Pharmaceuticals was traded for 245.44 at the closing time. The top price for the day was 247.16 and the lowest listed price was 236.45 . There was no trading activity during the period 0.0. Lack of trading volume on December 22, 2024 did not affect price variability. The overall trading delta against the current closing price is 2.44% . |
Alnylam Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Alnylam Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Alnylam financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Alnylam Pharmaceuticals Stock history
Alnylam Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Alnylam is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Alnylam Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Alnylam Pharmaceuticals stock prices may prove useful in developing a viable investing in Alnylam Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 124.9 M | 70.4 M | |
| Net Loss | -1 B | -967.1 M |
Alnylam Pharmaceuticals Quarterly Net Working Capital |
|
Alnylam Pharmaceuticals Stock Technical Analysis
Alnylam Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Alnylam Pharmaceuticals Period Price Range
Low | December 22, 2024
| High |
0.00 | 0.00 |
Alnylam Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Alnylam Pharmaceuticals December 22, 2024 Market Strength
Market strength indicators help investors to evaluate how Alnylam Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Alnylam Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Alnylam Pharmaceuticals stock market strength indicators, traders can identify Alnylam Pharmaceuticals entry and exit signals to maximize returns
Alnylam Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Alnylam Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Alnylam Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Alnylam to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.23) | |||
| Treynor Ratio | (0.12) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.